Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth and by blocking blood flow to the tumor. This phase II trial is studying the
side effects and how well sunitinib malate works in treating patients with Kaposi sarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)